子宫内膜异位症管理趋势:一项美国10年理赔分析
该观察性回顾研究基于2009至2022年两个美国医保理赔数据库,纳入OPTUM® 22 317例和MarketScan® 54 630例16-45岁子宫内膜异位症女性,分析治疗模式。多数患者诊断后接受手术(71.0% OPTUM®,72.1% MarketScan®),手术常作为一线干预,阿片类药物仍频繁一线使用。
要点
- 多数子宫内膜异位症患者诊断后接受手术,手术较药物治疗更常用。
- 手术作为一线干预的比例在OPTUM®为37.6%,MarketScan®为41.8%。
- 阿片类药物一线使用率OPTUM® 12.5%、MarketScan® 12.7%,与指南推荐相反。
核心结论
- 子宫内膜异位症治疗通常在诊断后4-6个月内开始。
- 手术比药物治疗使用更频繁,且多数情况下手术为一线干预。
- 尽管有强烈指南推荐不使用阿片类药物,阿片类药物仍频繁处方。
研究设计与样本
- 观察性回顾研究,2009年至2022年,使用MarketScan®和OPTUM®两个美国大型医保理赔数据库。
- 纳入16-45岁、持续参保且有至少2次子宫内膜异位症诊断的女性;排除子宫切除术、绝经或活动性恶性肿瘤治疗者。
- OPTUM®共22 317例,MarketScan®共54 630例。
主要发现
- 诊断后接受手术者占71.0%(OPTUM®)和72.1%(MarketScan®),接受药物治疗者占42.1%(OPTUM®)和44.9%(MarketScan®)。
- 手术作为一线干预者占37.6%(n=8395,其中腹腔镜4481例、子宫切除术3914例,OPTUM®)和41.8%(n=22 858,其中腹腔镜13 175例、子宫切除术9683例,MarketScan®)。
- 一线手术中腹腔镜占53.4%(n=4481,OPTUM®)和57.6%(n=13 175,MarketScan®),子宫切除术占46.6%(n=3914,OPTUM®)和42.4%(n=9683,MarketScan®)。
- 药物治疗作为一线者占49.9%(n=11 135,OPTUM®)和45.5%(n=24 840,MarketScan®);阿片类药物一线使用占12.5%(n=2787,OPTUM®)和12.7%(n=6932,MarketScan®)。
- 药物治疗作为一线干预在15-23周内开始,手术在诊断后16-18周内进行;有妇科合并症者诊断至治疗间隔短于精神健康和疼痛合并症者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To examine real-world treatment patterns for endometriosis and their alignment with clinical best-practice recommendations. DESIGN: Observational, retrospective study from 2009 to 2022. SETTING: Two large US health insurance claims databases, MarketScan® and OPTUM®. PATIENTS: Women aged 16-45 years with continuous enrollment in OPTUM® and MarketScan® and at least 2 diagnoses of endometriosis. Hysterectomy, menopause or active treatment of malignancy were exclusion criteria. INTERVENTIONS: Pharmacological therapy (including OCPs, POPs, GnRH analogs, opioids), and surgical management (including laparoscopy and hysterectomy). MEASUREMENTS: Frequencies, means, Time-to-event Kaplan-Meier curves, and Sankey diagrams were used to examine treatment initiation, frequencies and sequences. MAIN RESULTS: A total of 22 317 participants from OPTUM® and 54 630 from MarketScan® were included. Most of these patients (71.0% OPTUM®, 72.1% MarketScan®) received surgery after diagnosis of endometriosis, whereas medications were prescribed in 42.1% (OPTUM®) and 44.9% (MarketScan®). Surgery was performed as a first-line intervention in 37.6% (n = 8395, including 4481 laparoscopies and 3914 hysterectomies in OPTUM®) and 41.8% (n = 22 858, including 13 175 laparoscopies and 9683 hysterectomies in MarketScan®). Among first-line surgeries (n = 8395 OPTUM®, n = 22 858 MarketScan®), laparoscopies accounted for over half (53.4%, n = 4481 OPTUM®; 57.6%, n = 13 175 MarketScan®), while hysterectomies comprised nearly half (46.6%, n = 3914 OPTUM®; 42.4%, n = 9683 MarketScan®). Pharmacotherapy was used first-line in 49.9% (n = 11 135) of OPTUM® and 45.5% (n = 24 840) of MarketScan®. Opioids were used first-line in 12.5% (n = 2787) OPTUM® and 12.7% (n = 6932) MarketScan®. Pharmacological therapies were started as first-line intervention within 15-23 weeks, and surgeries were performed within 16-18 weeks after diagnosis. Those with gynecologic comorbidities had a shorter diagnosis-to-treatment interval than those with mental health and pain comorbidities. CONCLUSION: Therapies for endometriosis are generally started within 4-6 months of diagnosis. Surgery is used more frequently than medical management, and in the majority of cases, surgery was first-line intervention. Opioids are still frequently prescribed despite strong guidelines recommending against their use.
引用
- Lewis H, AsadZadeh V K PF, Soskin L, et al. Trends in Endometriosis Management: A 10-Year US Claims Analysis. J Minim Invasive Gynecol. 2025. PMID: 40967302. doi:10.1016/j.jmig.2025.09.519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。